SpringerLink
Log in

The Role of Nuclear Medicine in Map** Sentinel Lymph Nodes and Staging Metastatic Melanoma

  • Chapter
  • First Online:
Current Management of Melanoma

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 424 Accesses

Abstract

Malignant melanoma is the most aggressive and lethal skin cancer. It can metastasize in the locoregional nodes or in distant lymph node districts following sometimes unpredictable paths. Nuclear medicine plays a key role in map** sentinel lymph nodes and staging metastatic disease. It also provides an important contribution to the management of therapy by monitoring the response to treatment allowing a simultaneous evaluation of the metabolic and anatomical characteristics of the primary tumor and its potential local, regional and distance extension, especially in patients with high-risk disease. A variety of techniques are used including radioguided surgery and new hybrid imaging tools, such as positron emission tomography (PET/CT) with fluorine-18-fluorodeoxyglucose (18F-FDG). In this chapter, we review the clinical contribution of current nuclear medicine technologies to the management of malignant melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

eBook
USD 27.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 27.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Moncayo VM, Aarsvold JN, Alazraki NP. Lymphoscintigraphy and sentinel nodes. J Nucl Med. 2015;56(6):901–7.

    PubMed  Google Scholar 

  2. Tew K, Farlow D. SPECT/CT in melanoma lymphoscintigraphy. Clin Nucl Med. 2016;41(12):961–3.

    PubMed  Google Scholar 

  3. Lawal I, Lengana T, Ololade K, et al. (18)F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence. Nuklearmedizin. 2017;56(3):83–9.

    PubMed  Google Scholar 

  4. Wong ANM, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):67–77.

    PubMed  Google Scholar 

  5. Cabañas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39(2):456–66.

    PubMed  Google Scholar 

  6. Uren RF, Nieweg OE, Thompson JF. Sentinel lymph node biopsy: evolution of the technique since the original description by Morton et al. in 1992. Crit Rev Oncog. 2016;21(1–2):7–17.

    PubMed  Google Scholar 

  7. Leong SP, Wu M, Lu Y, et al. Intraoperative imaging with a portable gamma camera may reduce the false-negative rate for melanoma sentinel lymph node surgery. Ann Surg Oncol. 2018;25(11):3326–33.

    PubMed  PubMed Central  Google Scholar 

  8. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.

    PubMed  PubMed Central  Google Scholar 

  9. Bluemel C, Herrmann K, Giammarile F, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging. 2015;42(11):1750–66.

    PubMed  Google Scholar 

  10. Ortega Candil A, Rodríguez Rey C, Carreras Delgado JL. Malignant melanoma. ISRN Dermatol. 2012;2012:308279. https://doi.org/10.5402/2012/308279.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143(9):892–9.

    PubMed  PubMed Central  Google Scholar 

  12. Perissinotti A, Rietbergen DD, Vidal-Sicart S, et al. Melanoma & nuclear medicine: new insights & advances. Melanoma Manag. 2018;5(1):MMT06. https://doi.org/10.2217/mmt-2017-0022.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mays MP, Martin RC, Burton A, et al. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer. 2010;116(6):1535–44.

    PubMed  Google Scholar 

  14. Gajdos C, Griffith KA, Wong SL, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer. 2009;115(24):5752–60.

    PubMed  Google Scholar 

  15. Belhocine TZ, Scott AM, Even-Sapir E, et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med. 2006;47(6):957–67.

    PubMed  Google Scholar 

  16. Nieweg OE, Veenstra HJ. False-negative sentinel node biopsy in melanoma. J Surg Oncol. 2011;104(7):709–10.

    PubMed  Google Scholar 

  17. Bagaria SP, Faries MB, Morton DL. Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer institute. J Surg Oncol. 2010;101(8):669–76.

    PubMed  PubMed Central  Google Scholar 

  18. Solari N, Gipponi M, Stella M, et al. Predictive role of preoperative lymphoscintigraphy on the status of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma. Melanoma Res. 2009;19(4):243–51.

    PubMed  Google Scholar 

  19. Gipponi M, Di Somma C, Peressini A, et al. Sentinel lymph node biopsy in patients with stage I/II melanoma: clinical experience and literature review. J Surg Oncol. 2004;85(3):133–40.

    PubMed  Google Scholar 

  20. Villa G, Agnese G, Bianchi P, et al. Map** the sentinel lymph node in malignant melanoma by blue dye, lymphoscintigraphy and intraoperative gamma probe. Tumori. 2000;86(4):343–5.

    CAS  PubMed  Google Scholar 

  21. Cafiero F, Peressini A, Percivale PL, et al. Selective lymph node dissection in patients with intermediate thickness melanoma: our experience. Anticancer Res. 2000;20(1B):497–500.

    CAS  PubMed  Google Scholar 

  22. Vidal-Sicart S, Vera DR, Valdés Olmos RA. Next generation of radiotracers for sentinel lymph node biopsy: what is still necessary to establish new imaging paradigms? Rev Esp Med Nucl Imagen Mol. 2018;37(6):373–9.

    CAS  PubMed  Google Scholar 

  23. Surasi DS, O’Malley J, Bhambhvani P. 99mTc-tilmanocept: a novel molecular agent for lymphatic map** and sentinel lymph node localization. J Nucl Med Technol. 2015;43(2):87–91.

    PubMed  Google Scholar 

  24. Moncayo VM, Alazraki AL, Alazraki NP, Aarsvold JN. Sentinel lymph node biopsy procedures. Semin Nucl Med. 2017;47(6):595–617.

    PubMed  Google Scholar 

  25. Sondak VK, King DW, Zager JS, et al. Combined analysis of phase III trials evaluating [99mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20(2):680–8.

    PubMed  Google Scholar 

  26. Schaafsma BE, Mieog JSD, Hutteman M, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol. 2011;104(3):323–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Stoffels I, Dissemond J, Pöppel T, et al. Intraoperative fluorescence imaging for sentinel lymph node detection: prospective clinical trial to compare the usefulness of indocyanine green vs technetium Tc 99m for identification of sentinel lymph nodes. JAMA Surg. 2015;150(7):617–23.

    PubMed  Google Scholar 

  28. Crane LMA, Themelis G, Pleijhuis RG, et al. Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol. 2011;13(5):1043–9.

    PubMed  Google Scholar 

  29. Rossi EC, Ivanova A, Boggess JF. Robotically assisted fluorescence-guided lymph node map** with ICG for gynecologic malignancies: a feasibility study. Gynecol Oncol. 2012;124(1):78–82.

    PubMed  Google Scholar 

  30. Namikawa K, Tsutsumida A, Tanaka R, et al. Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma. Int J Clin Oncol. 2014;19(1):198–203.

    CAS  PubMed  Google Scholar 

  31. van den Berg NS, Brouwer OR, Schaafsma BE, et al. Multimodal surgical guidance during sentinel node biopsy for melanoma: combined gamma tracing and fluorescence imaging of the sentinel node through use of the hybrid tracer indocyanine green-99mTc-nanocolloid. Radiology. 2015;275(2):521–9.

    PubMed  Google Scholar 

  32. Stoffels I, Leyh J, Pöppel T, et al. Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-(99m)Tc-nanocolloid hybrid tracer versus (99m)Tc-nanocolloid. Eur J Nucl Med Mol Imaging. 2015;42(11):1631–8.

    CAS  PubMed  Google Scholar 

  33. Knackstedt RW, Couto RA, Gastman B. Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in head and neck melanoma. J Surg Res. 2018;228:77–83.

    PubMed  Google Scholar 

  34. Van Oosterom MN, Rietbergen DDD, Welling MM, et al. Recent advances in nuclear and hybrid detection modalities for image-guided surgery. Expert Rev Med Devices. 2019;16(8):711–34.

    PubMed  Google Scholar 

  35. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9(7):646–53.

    PubMed  Google Scholar 

  36. **ng Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129–42.

    PubMed  PubMed Central  Google Scholar 

  37. Krug B, Crott R, Lonneux M, et al. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology. 2008;249(3):836–44.

    PubMed  Google Scholar 

  38. Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141(3):284–8.

    PubMed  Google Scholar 

  39. Iagaru A, Quon A, Johnson D, et al. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2007;9(1):50–7.

    CAS  PubMed  Google Scholar 

  40. Petersen H, Holdgaard PC, Madsen PH, et al. FDG PET/CT in cancer: comparison of actual use with literature-based recommendations. Eur J Nucl Med Mol Imaging. 2016;43(4):695–706.

    PubMed  Google Scholar 

  41. Wagner T, Meyer N, Zerdoud S, et al. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. Br J Dermatol. 2011;164(6):1235–40.

    CAS  PubMed  Google Scholar 

  42. Malik D, Sood A, Mittal BR, et al. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery. World J Nucl Med. 2019;18(2):176–82.

    PubMed  PubMed Central  Google Scholar 

  43. Engell-Noerregaard L, Hendel HW, Johannesen HH, et al. FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunol Immunother. 2013;62(1):17–25.

    CAS  PubMed  Google Scholar 

  44. Jouvet JC, Thomas L, Thomson V, et al. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol. 2014;28(2):176–85.

    CAS  PubMed  Google Scholar 

  45. Buchbender C, Heusner TA, Lauenstein TC, et al. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53(8):1244–52.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, Department of Diagnostic Imaging and Radiation Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Giuseppe Villa & Federico Schenone

Authors
  1. Giuseppe Villa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federico Schenone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Villa .

Editor information

Editors and Affiliations

  1. Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Ferdinando Cafiero

  2. Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Franco De Cian

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Villa, G., Schenone, F. (2021). The Role of Nuclear Medicine in Map** Sentinel Lymph Nodes and Staging Metastatic Melanoma. In: Cafiero, F., De Cian, F. (eds) Current Management of Melanoma. Updates in Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-45347-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45347-3_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45346-6

  • Online ISBN: 978-3-030-45347-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation